COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K Current Report: March 19, 2026
Filed: March 19, 2026
Health Care
Pharmaceutical PreparationsCOLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 7.01: Regulation FD Disclosure
COLLEGIUM PHARMACEUTICAL, INC 8-K Mar 19, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Collegium Pharma to acquire AZSTARYS ADHD drug for $650M cash plus up to $135M in regulatory/commercial milestone payments
- • Acquisition targets GPC Commave Holding LLC and NewCo from Corium subsidiaries, expanding CNS stimulant portfolio
- • Closing expected in Q2 2026, subject to Hart-Scott-Rodino clearance and customary conditions
- • Termination fee $24M payable by Collegium if deal fails under specified conditions, indicating deal seriousness
- • Strategic move to enhance ADHD treatment offerings with a commercially approved drug, potentially boosting future revenues
Item 7.01 · Regulation FD Disclosure
- • Announcement of AZSTARYS® acquisition signals strategic expansion of COLLEGIUM's ADHD portfolio and commercial footprint
- • Presentation and press release from March 19, 2026 provide details on acquisition rationale and expected financial impact
- • Forward-looking statements highlight risks on closing timing, regulatory approvals, integration, and realization of anticipated benefits
- • Key risks include possible delays, failure of transaction, unknown liabilities, litigation, and competitive market challenges
- • Investors should monitor subsequent filings for updates on transaction progress, financial forecasts, and potential operational disruptions
Other COLLEGIUM PHARMACEUTICAL, INC 8-K Filings
Get deeper insights on COLLEGIUM PHARMACEUTICAL, INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.